Literature DB >> 9427606

Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression.

C N Papandreou1, B Usmani, Y Geng, T Bogenrieder, R Freeman, S Wilk, C L Finstad, V E Reuter, C T Powell, D Scheinberg, C Magill, H I Scher, A P Albino, D M Nanus.   

Abstract

Neutral endopeptidase 24.11 (NEP) is a cell-surface enzyme expressed by prostatic epithelial cells that cleaves and inactivates neuropeptides implicated in the growth of androgen-independent prostate cancer (PC). We report that NEP expression and catalytic activity are lost in vitro in androgen-independent but not androgen-dependent PC cell lines. In vivo, NEP protein expression is commonly decreased in cancer cells of metastatic PC specimens from patients with androgen-independent but not androgen-dependent PC. Overexpression of NEP in androgen-independent PC cells or incubation with recombinant NEP inhibits PC cell growth. Furthermore, in androgen-dependent PC cells, expression of NEP is transcriptionally regulated by androgen and decreases with androgen withdrawal. These data suggest that decreased NEP expression, common in androgen-independent PCs, is facilitated by the elimination of androgens, and that NEP loss plays an important role in the development of androgen-independent PC by allowing PC cells to use mitogenic neuropeptides as an alternate source to androgen in order to stimulate cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9427606     DOI: 10.1038/nm0198-050

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  56 in total

1.  Characterization of prostate cell types by CD cell surface molecules.

Authors:  Alvin Y Liu; Lawrence D True
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

2.  Candidate biomarkers in exosome-like vesicles purified from rat and mouse urine samples.

Authors:  Javier Conde-Vancells; Eva Rodriguez-Suarez; Esperanza Gonzalez; Agustin Berisa; David Gil; Nieves Embade; Mikel Valle; Zigmund Luka; Felix Elortza; Conrad Wagner; Shelly C Lu; Jose M Mato; M Falcon-Perez
Journal:  Proteomics Clin Appl       Date:  2010-04       Impact factor: 3.494

3.  Activity-based probes for the proteomic profiling of metalloproteases.

Authors:  Alan Saghatelian; Nadim Jessani; Arul Joseph; Mark Humphrey; Benjamin F Cravatt
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-25       Impact factor: 11.205

Review 4.  Endothelin receptor antagonists.

Authors:  Joel B Nelson
Journal:  World J Urol       Date:  2005-01-15       Impact factor: 4.226

5.  TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.

Authors:  Z Mounir; F Lin; V G Lin; J M Korn; Y Yu; R Valdez; O H Aina; G Buchwalter; A B Jaffe; M Korpal; P Zhu; M Brown; R D Cardiff; J L Rocnik; Y Yang; R Pagliarini
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

6.  Computer modeling and nanosecond simulation of the enzyme-substrate complex of the common lymphoblastic leukemia antigen (neprilysin) indicates shared residues at the primary specificity pocket (S1') with matrix metalloproteases.

Authors:  Sergio Manzetti
Journal:  J Mol Model       Date:  2003-08-29       Impact factor: 1.810

7.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

8.  Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease.

Authors:  Nikolai D Belyaev; Natalia N Nalivaeva; Natalia Z Makova; Anthony J Turner
Journal:  EMBO Rep       Date:  2008-12-05       Impact factor: 8.807

9.  Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent.

Authors:  Adolfo Varona; Lorena Blanco; Itxaro Perez; Javier Gil; Jon Irazusta; José I López; M Luz Candenas; Francisco M Pinto; Gorka Larrinaga
Journal:  BMC Cancer       Date:  2010-05-11       Impact factor: 4.430

10.  CD10 expression in urothelial carcinoma of the bladder.

Authors:  Burak Bahadir; Kemal Behzatoglu; Sibel Bektas; Erol R Bozkurt; Sukru O Ozdamar
Journal:  Diagn Pathol       Date:  2009-11-16       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.